You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
悅康藥業(688658.SH):子公司YKYY029注射液獲得國家藥品監督管理局臨牀試驗批準

格隆匯7月17日丨悅康藥業(688658.SH)公佈,公司子公司北京悅康科創醫藥科技股份有限公司(稱“悅康科創”)、杭州天龍藥業有限公司(稱“杭州天龍”)於近日獲得國家藥品監督管理局(稱“NMPA”)覈準簽發的關於YKYY029注射液用於治療高血壓的《藥物臨牀試驗批準通知書》,公司將開展本品I期臨牀試驗。

YKYY029注射液作爲一款siRNA藥物,其獨特之處在於偶聯了公司自主研發的、具有完全自主知識產權的GalNAc遞送系統。該系統已獲得國家知識產權局發明專利授權,並同步完成了PCT國際申請,能夠實現高效的肝靶向遞送。YKYY029注射液通過siRNA的幹擾沉默機制,從源頭靶向沉默AGTmRNA,有效阻斷AGT蛋白的合成。AGT蛋白作爲腎素-血管緊張素-醛固酮系統(Renin-angiotensin-aldosteronesystem,RAAS)的上遊蛋白,抑制其表達將從根本上抑制RAAS系統升高血壓的作用,從而降低血壓。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account